MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

急性膵炎

  • Home
  • 急性膵炎
More is Not Always Better: The GOULASH Trial Challenges High-Energy Early Nutrition in Acute Pancreatitis
Posted inGastroenterology Internal Medicine news

More is Not Always Better: The GOULASH Trial Challenges High-Energy Early Nutrition in Acute Pancreatitis

Posted by By MedXY 03/07/2026
The multicentre GOULASH trial reveals that high-energy nutrition in the early phase of acute pancreatitis does not improve outcomes and may increase risks of organ failure and pain relapse compared to a gradual caloric increase, leading to the trial's early termination for futility.
Read More
Can a Peripheral Opioid Antagonist Break the Cycle of Recurrent Acute Pancreatitis? Insights from the PAMORA-RAP Trial
Posted inGastroenterology Internal Medicine news

Can a Peripheral Opioid Antagonist Break the Cycle of Recurrent Acute Pancreatitis? Insights from the PAMORA-RAP Trial

Posted by By MedXY 02/02/2026
The PAMORA-RAP trial suggests that naldemedine, a peripherally acting μ-opioid receptor antagonist, may reduce the risk of recurrent acute pancreatitis by nearly 50%, offering a potential first-in-class pharmacological strategy for this high-burden condition.
Read More
  • Decoding Pancreatic Islet Single-Cell Transcriptomic Diversity Across Type 2 Diabetes Subtypes
  • Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Glucose Metabolism in Youths with Cystic Fibrosis: Insights from Continuous Glucose Monitoring
  • Approach to the Patient: Theranostics as Precision Medicine for Neuroendocrine Tumors
  • Charcot Neuro-Osteoarthropathy in Diabetes: High Risk of Hospitalization, Amputation, and Mortality Revealed by Regional Cohort Study
  • Gestational Diabetes Mellitus: Insights from 25 Years of Research on Early Risk, Prevention, and Long-Term Outcomes
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top